Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
May 02 2019 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that management will host a conference
call and live audio webcast at 10 a.m. EDT on May 9,
2019, to review the first quarter ended March 31, 2019, financial
results and provide a business update.
To access the live conference call by phone, dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13688060. A live audio webcast will be
accessible from the Media & Investors page of Albireo’s
website, http://ir.albireopharma.com/. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the start time.
An archived version of the webcast will be available for replay
on the Events & Presentations section of the Media &
Investors page of Albireo’s website for 1 year following the
event.
About Albireo Albireo Pharma is a
clinical-stage biopharmaceutical company focused through its
operating subsidiary on the development of novel bile acid
modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, A4250, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in its initial target indication, progressive familial intrahepatic
cholestasis. Albireo’s clinical pipeline also includes two Phase 2
product candidates. Albireo’s elobixibat, approved
in Japan for the treatment of chronic constipation, is
the first ileal bile acid transporter (IBAT) inhibitor
approved anywhere in the world. Albireo was spun out
from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts,
and its key operating subsidiary is located in Gothenburg,
Sweden. For more information on Albireo, please
visit www.albireopharma.com.
Investor Contact:Hans
VitzthumLifeSci Advisors, LLC212-915-2568
Media Contact:Heather Anderson 6 Degrees
980-938-0260 handerson@6degreespr.com
Source: Albireo Pharma, Inc.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024